AMICUS THERAPEUTICS, INC. — Director's Dealing 2018

Apr 18, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-04-16

Reporting Person: RAAB MICHAEL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-16	Common Stock	M	5000	$10.53	Acquired	10814	Direct
2018-04-16	Common Stock	S	5000	$14.4115	Disposed	5814	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-16	Stock Options (right to buy)	$10.53	M	5000	Disposed	2018-06-10	Common Stock (5000)	Direct

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2018.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.39 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of the options were fully vested and exercisable as of April 16, 2018.